Laura A. Colangelo

Laura A. Colangelo

Auto-generated profile, based on publicly available information

Laura A. Colangelo

Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 April 2015 in Hepatology
Verified
Journal Article
Open access
PDF file
LVLisa B. VanWagner
Lisa B. VanWagner
JWJane E. Wilcox
Jane E. Wilcox
LCLaura A. Colangelo
Laura A. Colangelo
DLDonald M Lloyd-Jones
Donald M Lloyd-Jones
JCJ. Jeffrey Carr
J. Jeffrey Carr
SSSanjiv J. Shah
Sanjiv J. Shah
Nonalcoholic fatty liver disease (NAFLD) and heart failure (HF) are obesity‐related conditions with high cardiovascular mortality. Whether NAFLD is independently associated with subclinical myocardial remodeling or dysfunction among the general population is unknown. We performed a cross‐sectional analysis of 2,713 participants from the multicenter, community‐based Coronary Artery Risk Development in Young Adults (CARDIA) study who underwent concurrent computed tomography (CT) quantification of liver fat and comprehensive echocardiography with myocardial strain measured by speckle tracking during the Year‐25 examination (age, 43‐55 years; 58.8% female and 48.0% black). NAFLD was defined as liver attenuation ≤40 Hounsfield units after excluding other causes of liver fat. Subclinical left ventricular (LV) systolic dysfunction was defined using values of absolute peak global longitudinal strain (GLS). Diastolic dysfunction was defined using Doppler and tissue Doppler imaging markers. Prevalence of NAFLD was 10.0%. Participants with NAFLD had lower early diastolic relaxation (e’) velocity (10.8 ± 2.6 vs. 11.9 ± 2.8 cm/s), higher LV filling pressure (E/e’ ratio: 7.7 ± 2.6 vs. 7.0 ± 2.3), and worse absolute GLS (14.2 ± 2.4% vs. 15.2 ± 2.4%) than non‐NAFLD (P < 0.0001 for all). When adjusted for HF risk factors or body mass index, NAFLD remained associated with subclinical myocardial remodeling and dysfunction (P < 0.01). The association of NAFLD with e’ velocity (β = −0.36 [standard error = 0.15] cm/s;P = 0.02), E/e’ ratio (β = 0.35 [0.16];P = 0.03), and GLS (β = −0.42 [0.18]%;P = 0.02) was attenuated after controlling for visceral adipose tissue. Effect modification by race and sex was not observed.Conclusions:NAFLD is independently associated with subclinical myocardial remodeling and dysfunction and provides further insight into a possible link between NAFLD and HF. (Hepatology2015;62:773–783)

1 October 2009 in Nutrition
Verified
Journal Article
Closed access
LCLaura A. Colangelo
Laura A. Colangelo
KHKa He
Ka He
MWMary A. Whooley
Mary A. Whooley
MDMartha L. Daviglus
Martha L. Daviglus
KLKiang Liu
Kiang Liu

1 April 2002
Verified
Journal Article
Closed access
LCLaura A Colangelo
Laura A Colangelo
SGSusan M Gapstur
Susan M Gapstur
PGPeter H Gann
Peter H Gann
ADAlan R Dyer
Alan R Dyer
KLKiang Liu
Kiang Liu

16 March 2009 in Diabetes Care
Verified
Journal Article
Open access
LCLaura A. Colangelo
Laura A. Colangelo
POPamela Ouyang
Pamela Ouyang
KLKiang Liu
Kiang Liu
PKPeter Kopp
Peter Kopp
SGSherita Hill Golden
Sherita Hill Golden
SGSusan M. Gapstur
Susan M. Gapstur
OBJECTIVE: To assess associations of sex hormones with impaired fasting glucose (IFG) and type 2 diabetes in men. RESEARCH DESIGN AND METHODS: A total of 3,156 African American, Non-Hispanic white, Hispanic, and Chinese-American men aged 45–84 years who participated in the baseline visit of the Multi-Ethnic Study of Atherosclerosis (MESA) were included. Oddsratios and95% CIs for type 2 diabetes and IFG compared with normal fasting glucose for quartiles of hormones were estimated. RESULTS: After adjusting for age, ethnicity, BMI, and waist circumference, IFG and diabetes were associated inversely with total testosterone and sex hormone–binding globulin (SHBG) and positively with estradiol (E2). Dehydroepiandrosterone was positively associated with IFG but not with diabetes. Associations did not differ across ethnic groups. CONCLUSIONS: Regardless of obesity, total testosterone and SHBG were associated inversely and E2 was associated positively with IFG and diabetes in men. Further research is warranted to better understand the underlying biological mechanisms.

17 November 2020 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
RPRavi B. Patel
Ravi B. Patel
LCLaura A. Colangelo
Laura A. Colangelo
SBSuzette J. Bielinski
Suzette J. Bielinski
Nicholas B LarsonNicholas B Larson
Nicholas B Larson
JDJingzhong Ding
Jingzhong Ding
DLDonald M. Lloyd‐Jones
Donald M. Lloyd‐Jones
Background: Serum levels of vascular cell adhesion molecule‐1 (VCAM‐1) are reflective of endothelial activation. Although VCAM‐1 has been implicated in the pathogenesis of heart failure with preserved ejection fraction (HFpEF), the prospective association of VCAM‐1 with development of clinically overt heart failure (HF) across ejection fraction categories is unclear. Methods and Results: In MESA (the Multi‐Ethnic Study of Atherosclerosis), we evaluated the association of VCAM‐1 at examination 2 (2002–2004) with incident HF (HFpEF and HF with reduced ejection fraction) after adjustment for cardiovascular risk factors. Incident HF was independently adjudicated as first hospitalization for symptomatic HF. Among 2297 participants (mean age, 63 years; women, 53%), those with higher VCAM‐1 were more likely to be White race, had higher blood pressure, and had lower kidney function. Over a median of 14.4 years, there were 102 HF events (HFpEF=65; HF with reduced ejection fraction=37). After covariate adjustment, each doubling of VCAM‐1 was associated with incident HF (hazard ratio [HR], 1.94; 95% CI, 1.17–3.23; P =0.01). This association appeared stronger among current/former smokers compared with never smokers. On evaluation of HF subtypes, VCAM‐1 was associated with incident HFpEF (HR, 1.97; 95% CI, 1.04–3.72; P =0.04) but not with incident HF with reduced ejection fraction, although risk estimates were consistent (HR, 1.82; 95% CI, 0.79–4.21; P =0.16). Conclusions: In a multiethnic cohort, VCAM‐1 was significantly associated with incident HF over long‐term follow‐up. These findings suggest a potential role for endothelial activation in driving clinical HF, and specifically HFpEF. Therapies that decrease endothelial activation may prevent the progression from cardiovascular risk factors to clinical HF.

15 March 2014 in Respiratory Research
Verified
Journal Article
Open access
PDF file
MMMichelle E Marchese
Michelle E Marchese
RKRajesh Kumar
Rajesh Kumar
LCLaura A Colangelo
Laura A Colangelo
PAPedro C Avila
Pedro C Avila
DJDavid Jacobs
David Jacobs
JCJoan Cook-Mills
Joan Cook-Mills
Clinical studies of the associations of vitamin E with lung function have reported conflicting results. However, these reports primarily examine the α-tocopherol isoform of vitamin E and have not included the isoform γ-tocopherol which we recently demonstrated in vitro opposes the function of α-tocopherol. We previously demonstrated, in vitro and in animal studies, that the vitamin E isoform α-tocopherol protects, but the isoform γ-tocopherol promotes lung inflammation and airway hyperresponsiveness. To translate these findings to humans, we conducted analysis of 4526 adults in the Coronary Artery Risk Development in Young Adults (CARDIA) multi-center cohort with available spirometry and tocopherol data in blacks and whites. Spirometry was obtained at years 0, 5, 10, and 20 and serum tocopherol was from years 0, 7 and 15 of CARDIA. In cross-sectional regression analysis at year 0, higher γ-tocopherol associated with lower FEV1 (p = 0.03 in blacks and p = 0.01 in all participants) and FVC (p = 0.01 in blacks, p = 0.05 in whites, and p = 0.005 in all participants), whereas higher α-tocopherol associated with higher FVC (p = 0.04 in blacks and whites and p = 0.01 in all participants). In the lowest quartile of α-tocopherol, higher γ-tocopherol associated with a lower FEV1 (p = 0.05 in blacks and p = 0.02 in all participants). In contrast, in the lowest quartile of γ-tocopherol, higher α-tocopherol associated with a higher FEV1 (p = 0.03) in blacks. Serum γ-tocopherol >10 μM was associated with a 175–545 ml lower FEV1 and FVC at ages 21–55 years. Increasing serum concentrations of γ-tocopherol were associated with lower FEV1 or FVC, whereas increasing serum concentrations of α-tocopherol was associated with higher FEV1 or FVC. Based on the prevalence of serum γ-tocopherol >10 μM in adults in CARDIA and the adult U.S. population in the 2011 census, we expect that the lower FEV1 and FVC at these concentrations of serum γ-tocopherol occur in up to 4.5 million adults in the population.